Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the pharmacokinetics of vildagliptin and its metabolites in patients with mild, moderate or severe renal impairment and healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

NCT00572650

Type 2 Diabetes Mellitus

COMPLETED PHASE1

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

NCT00818571

Renal Impairment Diabetes

COMPLETED PHASE1/PHASE2

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

NCT00765830

Diabetes Mellitus, Type 2 Renal Insufficiency

COMPLETED PHASE3

A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

NCT00501462

Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2 Renal Insufficiency

COMPLETED PHASE1

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

NCT04616027

Diabetes Mellitus, Type 2 Renal Impairment Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type-2 Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Vildagliptin

Group Type EXPERIMENTAL

vildagliptin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vildagliptin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LAF237

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women (age 18 to 85 years)
* Participants must be nonfertile or using a medically approved birth control method. Additional information regarding this requirement available at screening
* Body mass index (BMI) ≤42 kg/m2 (inclusive)

* Patients with mild, moderate, or severe kidney impairment. Please consult with participating physicians regarding the definitions of these levels of severity.
* Patients with diabetes must be treated with standard anti-diabetic therapy (diet and exercise, stable dose of sulfonylurea, insulin, or metiglinides) and agree to continue for the study duration

* No current significant medical conditions as determined by history and physical.
* Serum creatinine with a calculated creatinine clearance (CrCl) of \>80 ml/min.
* Matched to renal impaired patients in the study by age (±5 years), sex and weight (±10% BMI)
* Vital signs guided by the following ranges:

oral body temperature between 35.0-37.2 °C systolic blood pressure, 100-140 mm Hg diastolic blood pressure, 60-110 mm Hg pulse rate, 45-90 bpm

Exclusion Criteria

* Pregnant or lactating female.
* A history of type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, acute metabolic diabetic complications (eg, ketoacidosis or hyperosmolar state (coma))
* Subjects that have been enrolled in previous vildagliptin studies or other DPP
* 4 inhibitor studies within six months
* History of renal transplant or immunosuppressant therapy
* Acute infections which may affect blood glucose control or other medical condition that may interfere with the interpretation of efficacy and safety data during the study
* Any pre-existing or history of diabetic ulcer
* Any of the following within the past 6 months: myocardial infarction (MI), coronary artery bypass surgery or percutaneous coronary intervention, unstable angina or stroke
* Any of the following electrocardiogram (ECG) abnormalities: Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation, second degree atrioventricular (AV) block (Mobitz 1 and 2), third degree AV block, prolonged QTc (\>500 ms)
* Malignancy including leukemia and lymphoma within the last 5 years.
* Liver disease such as cirrhosis or positive hepatitis B and C.
* Any alcohol related hepatic disease.
* Patients undergoing any method of dialysis
* Use of some concomitant medications
* Significant laboratory abnormalities as specified in the protocol
* History of active substance abuse (including alcohol) within the past 2 years.
* Smokers (i.e., 10 or more cigarettes per day)
* History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes